MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$104,997K
(0.13%↑ Y/Y)
Net loss
-$104,994K
(0.31%↑ Y/Y)
Unrealized (loss) gain on
marketable securities
-$3K
(-101.67%↓ Y/Y)
Interest and other
income, net
$10,349K
(-28.28%↓ Y/Y)
Loss before income
taxes
-$104,873K
(0.30%↑ Y/Y)
Income tax expense
$121K
(-7.63%↓ Y/Y)
Total other income,
net
$10,349K
(-28.28%↓ Y/Y)
Loss from operations
-$115,222K
(3.67%↑ Y/Y)
Revenue from
collaboration agreements
$35,947K
(1.02%↑ Y/Y)
Total operating
expenses
$151,169K
(-2.60%↓ Y/Y)
Research and development
$104,240K
(-5.78%↓ Y/Y)
General and
administrative
$36,196K
(-14.07%↓ Y/Y)
Impairment loss on
right-of-use asset
$10,733K
Back
Back
Income Statement
source: myfinsight.com
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)